GlobeNews Wire

Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes

ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced…

1 month ago

Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches

Sacramento, Dec. 18, 2025 (GLOBE NEWSWIRE) -- With the New Year fast approaching and consumer interest in weight loss solutions…

1 month ago

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

December 18, 2025 19:00 ET  | Source: Mesa Laboratories, Inc. LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories,…

1 month ago

Synopsys Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Synopsys, Inc. – SNPS

NEW ORLEANS, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until…

1 month ago

Clinic Secret Unveiled: How This GLP-1 Weight Loss Platform Enables At-Home Access to Ozempic, Semaglutide & Tirzepatide – Clinic Secret

Intro: Clinic Secret Enters the Spotlight as GLP-1 Telehealth Platforms Gain National Attention New York City, NY, Dec. 18, 2025…

1 month ago

CarMax Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against CarMax, Inc. – KMX

NEW ORLEANS, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until…

1 month ago

Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR

Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and ChinaStrengthens…

1 month ago

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

December 17, 2025 20:48 ET  | Source: InnoCare Pharma BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

1 month ago

Sapu BioScience Highlights TGFB2-Guided Strategy to Enhance Taxane Therapies, Reinforcing the Rationale for Sapu-001

San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience today announced the publication of a new peer-reviewed study…

1 month ago

Assembly Software Highlights 2025 Milestones as NeosAI Achieves Year-Over-Year Adoption Growth

CORAL GABLES, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) --  Assembly Software, a leading provider of AI-powered legal technology and cloud-based…

1 month ago